Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on June 24, 2019. The filing primarily addresses corporate governance changes, specifically the appointment of a new Chief Financial Officer and Secretary.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel appointments and related agreements.
Material Changes
The material change reported is the appointment of Carlo Campiciano as Chief Financial Officer (CFO) and Secretary of Propanc Biopharma, Inc., and CFO and Secretary of its wholly-owned subsidiary, Propanc PTY LTD. The appointment is effective as of July 1, 2019. Mr. Campiciano will also serve as the Principal Accounting Officer.
Management Commentary and Agreements
- Executive Background: Mr. Campiciano, age 64, is a qualified chartered accountant with over 30 years of experience. He previously served as CFO for MedAdvisor International Pty Ltd. and TGA Unlimited Pty Ltd., where he helped grow annual revenues from $2 million to over $40 million. He holds a US GAAP certification.
- Compensation Structure: Under the Employment Agreement with Propanc PTY, Mr. Campiciano will be compensated at an hourly rate based on a pro-rated annual salary corresponding to the hours of service provided.
- Termination Benefits: The agreement stipulates that upon termination by either party, Mr. Campiciano is entitled to accrued but untaken annual leave, pro-rated salary payments based on the notice period, and reimbursement of business expenses.
- Additional Agreements: The Company entered into a standard Indemnification Agreement with Mr. Campiciano. No family relationships exist between Mr. Campiciano and other officers or directors.
Investor Verification Checklist
- Verify the effective date of the CFO appointment (July 1, 2019) against internal corporate records.
- Review the full text of the Employment Agreement (Exhibit 10.1) to confirm the specific pro-rated salary calculation and hourly rate.
- Confirm the status of the Indemnification Agreement (Exhibit 10.2) and its terms.
- Check for any subsequent filings regarding the departure of the previous CFO or Secretary.